172 related articles for article (PubMed ID: 24382707)
1. Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.
Witzig TE; Maurer MJ; Stenson MJ; Allmer C; Macon W; Link B; Katzmann JA; Gupta M
Am J Hematol; 2014 Apr; 89(4):417-22. PubMed ID: 24382707
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.
Maurer MJ; Micallef IN; Cerhan JR; Katzmann JA; Link BK; Colgan JP; Habermann TM; Inwards DJ; Markovic SN; Ansell SM; Porrata LF; Johnston PB; Nowakowski GS; Thompson CA; Gupta M; Syrbu SI; Kurtin PJ; Macon WR; Nikcevich DA; Witzig TE
J Clin Oncol; 2011 Apr; 29(12):1620-6. PubMed ID: 21383282
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification.
Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Song JW; Yang WI; Kim JS
Ann Hematol; 2014 Nov; 93(11):1867-77. PubMed ID: 24947797
[TBL] [Abstract][Full Text] [Related]
4. Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma.
Witzig TE; Maurer MJ; Habermann TM; Link BK; Micallef IN; Nowakowski GS; Ansell SM; Colgan JP; Inwards DJ; Porrata LF; Markovic SN; Johnston PB; Lin Y; Thompson C; Gupta M; Katzmann JA; Cerhan JR
Am J Hematol; 2014 Dec; 89(12):1116-20. PubMed ID: 25228125
[TBL] [Abstract][Full Text] [Related]
5. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.
Ansell SM; Maurer MJ; Ziesmer SC; Slager SL; Habermann TM; Link BK; Witzig TE; Macon WR; Dogan A; Cerhan JR; Novak AJ
Am J Hematol; 2012 Sep; 87(9):865-9. PubMed ID: 22674570
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.
Jardin F; Delfau-Larue MH; Molina TJ; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Jais JP; Figeac M; Leroy K; Mareschal S; Salles GA; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Haioun C; Tilly H
Leuk Lymphoma; 2013 Sep; 54(9):1898-907. PubMed ID: 23327290
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.
Maurer MJ; Cerhan JR; Katzmann JA; Link BK; Allmer C; Zent CS; Call TG; Rabe KG; Hanson CA; Kay NE; Slager SL; Witzig TE; Shanafelt TD
Blood; 2011 Sep; 118(10):2821-6. PubMed ID: 21765023
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.
Gupta M; Stenson M; O'Byrne M; Maurer MJ; Habermann T; Cerhan JR; Weiner GW; Witzig TE
Ann Oncol; 2016 Jan; 27(1):165-72. PubMed ID: 26487586
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL).
Maiolo E; Alma E; Napodano C; Gulli F; Bellesi S; Cuccaro A; Pocino K; D'Alo' F; Iachini M; Martini M; Larocca LM; De Stefano V; Basile U; Hohaus S
Leuk Lymphoma; 2020 May; 61(5):1133-1139. PubMed ID: 31889454
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.
Thompson CA; Maurer MJ; Cerhan JR; Katzmann JA; Ansell SM; Habermann TM; Macon WR; Weiner GJ; Link BK; Witzig TE
Am J Hematol; 2011 Dec; 86(12):998-1000. PubMed ID: 22006790
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
Giachelia M; Voso MT; Tisi MC; Martini M; Bozzoli V; Massini G; D'Aló F; Larocca LM; Leone G; Hohaus S
Leuk Lymphoma; 2012 Mar; 53(3):411-6. PubMed ID: 21902578
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation.
Gupta M; Han JJ; Stenson M; Maurer M; Wellik L; Hu G; Ziesmer S; Dogan A; Witzig TE
Blood; 2012 Mar; 119(12):2844-53. PubMed ID: 22323454
[TBL] [Abstract][Full Text] [Related]
14. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.
Pardanani A; Lasho TL; Finke CM; Rajkumar SV; Singh PP; Ketterling RP; Hanson CA; Katzmann JA; Tefferi A
J Clin Oncol; 2012 Apr; 30(10):1087-94. PubMed ID: 22331938
[TBL] [Abstract][Full Text] [Related]
15. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
16. Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy.
Wang L; Liu P; Chen X; Geng Q; Lu Y
Med Oncol; 2012 Sep; 29(3):2153-8. PubMed ID: 21877195
[TBL] [Abstract][Full Text] [Related]
17. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
[TBL] [Abstract][Full Text] [Related]
19. Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology.
Winter JN
Curr Hematol Malig Rep; 2007 Oct; 2(4):235-41. PubMed ID: 20425375
[TBL] [Abstract][Full Text] [Related]
20. The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma.
Han X; Wang J; Zhang N; Yao J; Feng Y; Li D; Liu P; Yang J; Zhou S; Qin Y; Yang S; Gui L; He X; Shi Y
Leuk Res; 2014 Nov; 38(11):1291-8. PubMed ID: 25287608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
